CXCR4 and ovarian carcinoma: The same cells then could be used to test compounds and dosing schedules in mouse models of ovarian cancer, using CXCR4-β-arrestin 2 complementation to quantify inhibition of the receptor and fluorescence to measure overall tumor burden.